USO DE INIBIDORES DE COX-2 NO TRATAMENTO DO CARCINOMA DE CÉLULAS DE TRANSIÇÃO DE BEXIGA EM CÃES – REVISÃO

Autores

  • Paulo César Jark
  • Luiz Henrique de Araújo Machado
  • Maria Lúcia Gomes Lourenço Lourenço
  • Michiko Sakate

Palavras-chave:

bexiga, carcinoma de células de transição, COX-2, oncologia

Resumo

Nas últimas décadas diversos estudos têm sido realizados correlacionando o desenvolvimento e progressão de alguns tipos de neoplasias com a presença da cicloxigenase-2 (COX-2) e consequentemente superprodução de prostaglandinas nas células tumorais. Os mecanismos envolvidos neste processo são a inibição da  apoptose, a indução de angiogênese, o estímulo à proliferação celular, o aumento na capacidade de invasão tumoral (favorecendo os mecanismos de metástase) e a supressão do sistema imune. A partir destas observações, o uso de inibidores de COX-2 foi sugerido em alguns tipos de neoplasias especialmente no carcinoma de células de transição de bexiga.  Neste contexto, o presente trabalho consiste da revisão de literatura sobre o uso de inibidores de COX-2 no tratamento do carcinoma de células de transição de bexiga em cães.

Referências

Andrade SF. Antiinflamatórios. In: Manual de terapêutica veterinária. São Paulo: Roca;

p.89-113.

Groot DJA, Vries EGE, Groen HJM, Jong S. Non-steroidal anti-inflammatory drugs to

potentiate chemotheraphy effects: from lab to clinic. Crit Rev Oncol Hematol. 2007;61:52-

Hayes A. Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory dugs – can we

combine all three? Vet Comp Oncol. 2007;5:1-13.

Mohammed SI, Khan KNM, Sellers RS, Hayec MG, De Nicola DB, Wu L, et al.

Expression of cyclooxygenase-1 and 2 in naturally occurring canine cancer. Prostaglandins

Leukot Essent Fatty Acids. 2004;70:479-83.

Clifford CA. Cancer and non-steroidal drugs. In: Proceedings of North American

Veterinary Conference; 2005, Orlando. Orlando: NAVC; 2005. p.619.

Dhawan D, Jefreys AB, Zheng R, Stewart JC, Knapp DW. Cyclooxygenase-2 dependent

and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.

Mol Cancer Ther. 2008;7:897-904.

Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem.

;43:59-78.

Morrisom WB. Non-cytotoxic drugs in cancer treatment. In: Proceedings of North

American Veterinary Conference; 2007, Ithaca. Ithaca: NAVC; 2007.

Lloret A. The use of cox-2 drugs in oncology: clinical case. In: Proceedings of Southern

European Veterinary Conference; 2008, Barcelona. Barcelona: Avepa; 2008.

Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2) –

Independent anticarcinogenic effects of selective COX-2 Inhibitor. J Natl Cancer Inst.

;98:736-47.

Shyong D, Chen IH, Chang SY. The expression of cyclooxygenase in transitional cell

carcinoma cell lines: its correlation with tumor differentiation, invasiveness and

prostanoids production. Eur Urol. 2003;44:491-4.

Heller DA, Clifford CA, Goldschimidt MH, Holt DE, Manfredi MJ, Soreno KU.

Assessment of cyclooxygenase -2 expression in canine hemangiosarcoma, histiocytic

sarcoma e mast cell tumor. Vet Pathol. 2005;42:350-3.

Jang TJ, Lee KS. The expression ofcyclooxygenases-2 and surviving in urinary bladder

transitional cell carcinoma. Korean J Pathol. 2009;43:206-11.

Jones MK, Wang H, Pescar BM, Levin E, Itani RM, Sarfeh J, et al. Inhibition of

angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and

implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-23.

Macewen EG, Helfand SC. Immunology and biologic theraphy of cancer. In: Withrow

SJ, MacEwan EG. Small animal clinical oncology. 4ª ed. Philadelphia: W.B. Saunders;

p.99-111.

Knapp DW, Glickman WR, Denicola DB, Bonney PL, Tsang BS, Lawrence T, et al.

Naturally-occurring canine transitional cell carcinoma of urinary bladder: a revelant

model of human invasive bladder cancer. Urol Oncol. 2000;5:47-59.

Knapp DW, Glickman NW, Widmer WR, Denicola DB, Adams LG, Kuczec T, et al.

Cisplatin versus cisplatin combined with piroxican in a canine model of human ivasive

urinary bladder cancer. Cancer Chemother Pharmacol. 2000;46:221-6.

Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaer AJ, Snyder PW, et al.

Effects of the Cyclooxygenase inhibitor, Piroxican, on tumor response, apoptosis, and

angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res.

;62:356-8.

Boria PA, Glickman NW, Schimidt BR, Widmer WR, Mutsaers AJ, Adams LG, et al.

Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the

urinary bladder. Vet Comp Oncol. 2005;3:73-80.

Lee JY, Tanabe S, Shimoriha H, Kobayashi Y, Oomachi T, Azuma S, et al. Expression of

cyclooxygenase -2, P-glycoprotein and multi-drug resistance associated protein in canine

transitional cell carcinoma. Res Vet Sci. 2007;83:210-6.

Henry CJ. Transitional cell carcinoma. In: Proceedings of the 32º World Small Animal

Veterinary Association; 2007, Sydney. Sydney: Wsava; 2007.

Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, et al. Effects of

short-term Celecoxib treatment in patients with invasive transitional cell carcinoma of the

urinary bladder. Mol Cancer Ther. 2010;9:1371-7.

Daleck CR, De Nardi AB, Rodigheri SM, Motta FR. Neoplasia do sistema urinário. In:

Oncologia em cães e gatos. São Paulo: Roca; 2008. p.471-9.

Crow SE. Canine cancer genetics: transitional cell carcinoma in Scottish terrier. Cancer

Ther. 2008;6:177-80.

Nasir K, Khan M, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2

in transitional cell carcinoma of the urinary bladder in dog. Am J Vet Res. 2000;61:478-

Ristimaki A, Nieminem O, Saukkonen K, Hotakainem K, Nordling S, Haglund C.

Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary

bladder. Am J Pathol. 2001;158:849-53.

Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increase

with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol

Nephrol. 2005;37:47-53.

Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, Denicola DB, et al.

Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J

Vet Intern Med. 1994;8:273-8.

MohsenI H, Zaslau S, Mcfadden D, Riggs DR, Jackson BJ, Kandzari S. COX-2 inhibiton

demonstrates potent anti-proliferative effects on bladder cancer In vitro. J Surg Res.

;119:138-42.

Henry CJ, Mccaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, et al. Clinical

evaluation of mitoxantrone and piroxican in a canine model of human invasive urinary

bladder carcinoma. Clin Cancer Res. 2003;9:906-11.

Mutsaers AJ, Mohammed DB, Denicola DB, Snyder PW, Glickman PF, Bennett PF, et

al. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression

are not associated with the response of canine naturally occurring invasive urinary

bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty

Acids. 2005;72:181-6.

Downloads

Publicado

2022-08-10

Como Citar

1.
Jark PC, Machado LH de A, Lourenço MLGL, Sakate M. USO DE INIBIDORES DE COX-2 NO TRATAMENTO DO CARCINOMA DE CÉLULAS DE TRANSIÇÃO DE BEXIGA EM CÃES – REVISÃO. RVZ [Internet]. 10º de agosto de 2022 [citado 2º de novembro de 2024];18(4):523-30. Disponível em: https://rvz.emnuvens.com.br/rvz/article/view/1044

Edição

Seção

Artigos de Revisão

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 > >>